Pune biotech firm announces cheaper drug for colorectal cancer

[ad_1]

Pune-based biotech firm Enzene Biosciences has announced the launch of Bevacizumab, a biosimilar alternative to the more expensive Avastin that is used for treatment of metastatic colorectal cancer.

Bevacizumab is the sixth biosimilar from Enzene Biosciences’s pipeline. “Aimed at penetrating the Indian market for Bevacizumab that is valued at Rs 260 crore, Enzene’s version is the first to be manufactured using the firm’s patented continuous manufacturing process at its Pune facility,” said Dr. Himanshu Gadgil, CEO of Enzene Biosciences Ltd.

“We are confident that the significant price reductions passed on by our partners will greatly benefit thousands of metastatic colorectal cancer patients, supporting our mission to make cancer treatment more accessible and affordable,” he added.



[ad_2]

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Daily Horoscope for Friday, June 30, 2023, for all zodiac signs by astrologer Vinayak Vishwas Karandikar

Next Post

Check out the Tithi, Shubh Muhurat, Moon Sign, and Name Letter for Newborn on June 30, 2023

Related Posts
An agreement for trade finance has been signed between RBL Bank and Exim Bank.

An agreement for trade finance has been signed between RBL Bank and Exim Bank.

Mumbai-based RBL Bank has signed a Memorandum of Understanding (MoU) with Export-Import Bank of India (India Exim Bank) under the Trade Assistance Programme (TAP). The partnership aims to facilitate cross-border commercial operations by providing credit enhancement to trade instruments. RBL Bank is a private lender in India with a strong focus on digital banking and has a significant presence in the Indian financial market.
Read More